- $1.40bn
- $1.37bn
- $201.61m
Annual income statement for Enfusion, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 79.6 | 112 | 150 | 175 | 202 |
| Cost of Revenue | |||||
| Gross Profit | 58.2 | 79.9 | 103 | 117 | 137 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 73.5 | 388 | 162 | 163 | 195 |
| Operating Profit | 6.07 | -276 | -12 | 11.9 | 6.16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 4.49 | -282 | -12.2 | 11.5 | 7.39 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4.06 | -282 | -13.3 | 9.25 | 3.92 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 4.06 | -171 | -7.65 | 6.03 | 2.82 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 4.06 | -188 | -8.61 | 9.25 | 3.92 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.036 | -2.25 | -0.101 | 0.071 | 0.03 |
| Dividends per Share |